New DNA test could revolutionize diagnosis of eye infections

NCT ID NCT05286203

Completed Diagnosis Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new method called metagenomic deep sequencing (MDS) to find the cause of eye infections. 100 adults with suspected infectious uveitis or endophthalmitis were randomly assigned to have their doctors receive MDS results or not, in addition to standard tests. The goal was to see if MDS leads to more appropriate treatment and better vision outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Metagenomic Deep Sequencing (MDS) test
What this could lead to: If successful, MDS could become a faster, more accurate way to diagnose eye infections, helping doctors choose the right treatment sooner.
What could go wrong: This is a relatively small, early-stage trial. The test may not prove better than current methods, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFECTIOUS ANTERIOR UVEITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endophthalmitis infectious anterior uveitis infectious disease intermediate uveitis panuveitis posterior uveitis uveitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFECTIOUS DISEASE UVEITIS

Contacts and locations

Locations

University of California San Francisco (UCSF)

San Francisco, California, 94158, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.